DM
NBIX icon

Deerfield Management’s Neurocrine Biosciences NBIX Stock Holding History

Deerfield Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-610,000
Closed -$80.4M – 90
2026
Q1 		$80.4M Sell
610,000
-574,345
-48% -$76.2M 0.95% 33
2025
Q4 		$168M Hold
1,184,345
– – 2.15% 12
2025
Q3 		$166M Buy
1,184,345
+16,543
+1% +$2.24M 2.54% 9
2025
Q2 		$147M Sell
1,167,802
-321,198
-22% -$36.8M 2.66% 10
2025
Q1 		$165M Buy
1,489,000
+627,000
+73% +$79.4M 3.25% 4
2024
Q4 		$118M Sell
862,000
-454,590
-35% -$56.2M 2.23% 10
2024
Q3 		$152M Buy
1,316,590
+625,586
+91% +$85.8M 2.27% 8
2024
Q2 		$95.1M Hold
691,004
– – 1.58% 19
2024
Q1 		$95.3M Sell
691,004
-205,715
-23% -$28.1M 1.66% 20
2023
Q4 		$118M Sell
896,719
-312,995
-26% -$36M 2.18% 10
2023
Q3 		$136M Hold
1,209,714
– – 3% 7
2023
Q2 		$114M Sell
1,209,714
-535,000
-31% -$52.3M 2.44% 10
2023
Q1 		$177M Buy
1,744,714
+232,000
+15% +$24.1M 3.94% 3
2022
Q4 		$181M Hold
1,512,714
– – 3.74% 4
2022
Q3 		$161M Sell
1,512,714
-500,000
-25% -$50.7M 3.2% 5
2022
Q2 		$196M Buy
2,012,714
+354,914
+21% +$32.8M 4.05% 5
2022
Q1 		$155M Buy
1,657,800
+279,855
+20% +$23.7M 3.47% 6
2021
Q4 		$117M Buy
1,377,945
+235,530
+21% +$21.7M 2.46% 8
2021
Q3 		$110M Buy
1,142,415
+417,415
+58% +$39.4M 2.14% 10
2021
Q2 		$70.6M Hold
725,000
– – 1.25% 19
2021
Q1 		$70.5M Buy
+725,000
New +$76M 1.48% 17
2014
Q3 		– Sell
-53,094
Closed -$788K – 139
2014
Q2 		$788K Sell
53,094
-24,900
-32% -$351K 0.03% 113
2014
Q1 		$1.26M Buy
+77,994
New +$1.33M 0.05% 116

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Deerfield Management's NBIX Position: Q2 2026 in Review

Deerfield Management sold out of Neurocrine Biosciences (NBIX) in Q2 2026, closing a stake of 610,000 shares — an estimated $80.4M sold.

Deerfield Management first reported a position in NBIX in Q1 2014 and held it in 23 quarters. The position peaked at $196M in Q2 2022. 775 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Deerfield Management reported no remaining Neurocrine Biosciences position as of Q2 2026 after selling out during the quarter.
  • Deerfield Management sold 610,000 Neurocrine Biosciences shares in Q2 2026, an estimated $80.4M.
  • Deerfield Management first reported a position in Neurocrine Biosciences in Q1 2014 and held it in 23 quarters.
  • Deerfield Management's Neurocrine Biosciences position peaked at $196M in Q2 2022.
  • 775 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Deerfield Management's 13F filing for Q2 2026, filed 14 Aug 2026.